Fig. 1



(A)
CD81WT
LDLR
CD81-ΔLDLR
TFR
CD81-ΔTFR
extracellular
(B)
anti-CD81
anti-LDLR
anti-TFR
untransfected
CD81WT
CD81-ΔLDLR
CD81-ΔTFR
293T
Counts
FL1-H

Fig.2

(A)



Input
untransfected(total)
CD81WT(total)
CD81WT(internalizedl)
CD81-ΔTFR(total)
CD81-ΔTFR(internalized)
CD81-ΔLDLR(total)
CD81-ΔLDLR(internalized)
IgG heavy chain
Hsp70

Fig. 3.



CD81WT
CD81-ΔLDLR
CD81-ΔTFR
Geometric mean Fluorescence
800
700
600
500
400
300
200
100
0
0
0.5
1
2
3
4
6
7
8
incubation time at 37 C (h)

Fig. 4


(A)
E2/non-reducing
E2/reducing
Vec/reducing
111
80
61
(B)
untransfected
CD81WT
CD81-ΔTFR
CD81-ΔLDLR
myc-E2
80
61
36
actin

Fig. 5



Tet Induction (Days): - - 5 5
DNaseI and RNaseA treatment: - + - +
500 bp
300 bp
200 bp
plus strand RNA

Fig. 6



Huh7
Huh7-CD81WT
Huh7-CD81-ΔLDLR
Huh7-CD81-ΔTFR
Positive control
plus strand RNA (P1P5)
minus strand RNA (TAG/P4)
minus strand RNA (TAG/P5)
GAPDH

Fig. 7




(A)
-ve control
no treatment
anti-myc
anti-HCV E2
anti-mCD81
anti-hCD81
plus strand RNA (P1P5)
minus strand RNA (TAG/P4)
GAPDH
(B)
plus strand RNA (P1P5)
minus strand RNA (TAG/P4)
GAPDH

Fig. 8

(A)


ATGCAGCTGGATATGTTCTTCCTGATGGCAGTGGTTATAGGGGTCAATTCAGAGGTTCAGTTGCAGCAGTCTGGGGCTGAACTTGTGAGG
90
M Q L D M F F L M A V V I G V N S E V Q L Q Q S G A E L V R
CCAGGGGCCTCAGTCAAGTTGTCCTGCACAGCTTCTGGCTTTAACATTAAAGACGACTATATGCACTGGGTGAAGCAGAGGCCTGAACAG
180
P G A S V K L S C T A S G F N I K D D Y M H W V K Q R P E Q
GGCCTGGAGTGGATTGGATGGATTGATCCTGAAAATGGTGATACTGAATATGCCTCGAAGTTCCAGGGCAAGGCCACAATAACACCAGAC
270
G L E W I G W I D P E N G D T E Y A S K F Q G K A T I T P D
ACATCCTCCAACACAGCCTACCTGCAGCTCAGCAGCCTGACATCTGAGGACACTGCCGTCTATTACTGTATTACAAGGGGTAACTGGGGC
360
T S S N T A Y L Q L S S L T S E D T A V Y Y C I T R G N W G
CAAGGCACCACTCTNACAGTCTCCTCAGCCAAAACGACACCCCCATCTGTCTATCCACTGGCCCTGGATCTGCTGCCCAAACTAACTCCA
450
Q G T T L T V S S A K T T P P S V Y P L A L D L L P K L T P

(B)


ATGAAGTTTCCTTCTCAACTTCTGCTCTTCCTGCTGTTCAGAATCACAGGCATAATATGTGACATCCAGATGACACAATCTTCATCCTAC
90
M K F P S Q L L L F L L F R I T G I I C D I Q M T Q S S S Y
TTGTCTGTATCTCTAGGAGGCAGAGTCACCATTACTTGCGAGGCAAGTGACCACATTAATAATTGGTTAGCCTGGTATCAGCAGAAACCA
180
L S V S L G G R V T I T C E A S D H I N N W L A W Y Q Q K P
GGAAATGCTCCTAGGCTCTTAATATCTGGTGCAACCACTTTGGAAACTGGGGTTCCTTCAAGATTCAGTGGCAGTGGATCTGGAAAAGAT
270
G N A P R L L I S G A T T L E T G V P S R F S G S G S G K D
TACACTCTCAGCATTACCAGTCTTCAGACTGAAGATGTTGCTACTTATTACTGTCAACAGTATTGGGAGTCCTCCGTACACGTTCGGAGG
360
Y T L S I T S L Q T E D V A T Y Y C Q Q Y W E S S V H V R R
GGGGACCAAGCTGGAAATAAAACGGGC
387
G D Q A G N K T G

(A)




hybridoma
untransfected
IgL & IgH
IgL & IgH-ΔCI-MPR
IgL & IgH-ΔLDLR
untransfected
IgL & IgH
IgL & IgH-ΔCI-MPR
IgL & IgH-ΔLDLR
heavy chain
light chain
111kDa
60kDa
20kDa
extracellular
intracellular

Fig. 9

(B)


untransfected
IgL & IgH-ΔCI-MPR
IgL & IgH
IgL & IgH-ΔLDLR
Counts
FL1-H

(C)



heavy chain
light chain
293-IgH-ΔCIMPR
293-IgH-ΔLDLR

Fig. 10




before IP
after IP
gp120
~173kDa
~111kDa
IP with:
IgH only
IgH & IgL
hybridoma

Fig. 11

(A)



untransfected

293-IgH-ΔCI-MPR (clone 9)

293-IgH-ΔLDLR (clone 10)

(B)





Fig. 12



(C)


```
74  CCATGGCGTTAGTATGAGTGTCGTGCAGCCTCCAGGACCCCCCCTCCCGGGAGAGCCATAGTGGTCTGCG  HCV-BK
    ------------------------------------------------------------------------  HCV-1
    ------------------------------------------------------------------------  patient A
    ------------------------------------------------------------------------  patient B

144 GAACCGGTGAGTACACCGGAATTGCCAGGACGACCGGGTCCTTTCTTGGATCAACCCGCTCAATGCCTGG  HCV-BK
    ------------------------------------------------------------------------  HCV-1
    ------------------------------------------------------------------------  patient A
    ----------T-------------------------------------------------------------  patient B


214 AGATTTGGGCGTGCCCCCGCGAGACTGCTAGCCGAGTAGTGTTGGGTCGCGAAAGGCCTTGTGGT  HCV-BK
    ----------A-------------------------------------------------------------  HCV-1
    ------------------------------------------------------------------------  patient A
    ----------A-------------------------------------------------------------  patient B
```

Fig. 13

(A)


anti-c-myc
anti-HCV E2
neat
dil. 10X
dil. 30X
dil. 100X
neat
dil. 10X
dil. 30X
dil. 100X
300 bp
200 bp
positive strand
1 2 3 4 5 6 7 8 9

(B)


Huh7-CD81-LDLR
untransfected Huh7
Huh7-CD81WT
Huh7-TfR-CD81
Huh7-TfR-CD81/anti-HCV E2
Huh7-TfR-CD81/anti-c-myc
positive strand
GAPDH
1 2 3 4 5 6